Structural biology in the battle against BCR-Abl

Bibliography

• Levitzki A. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J 1992;6(14):3275-82
   PubMed Web of Science ®Google Scholar
• Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995;267(5205):1782-8
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2(5):561-6
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355(23):2408-17
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293(5531):876-80
   PubMed Web of Science ®Google Scholar
• Li S. Src kinase signaling in leukaemia. Int J Biochem Cell Biol 2007;39(7-8):1483-8
   PubMed Web of Science ®Google Scholar
• Cowan-Jacob SW, Fendrich G, Floersheimer A, et al. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D Biol Crystallogr 2007;63(Pt 1):80-93
   PubMed Web of Science ®Google Scholar
• Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997;13:513-609
   PubMed Web of Science ®Google Scholar
• Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004;4(6):470-80
   PubMed Web of Science ®Google Scholar
• Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001;2(6):467-75
   PubMed Web of Science ®Google Scholar
• Superti-Furga G, Courtneidge SA. Structure-function relationships in Src family and related protein kinases. Bioessays 1995;17:321-30
   PubMed Web of Science ®Google Scholar
• Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;19(49):5636-42
   PubMed Web of Science ®Google Scholar
• Chen T, George JA, Taylor CC. Src tyrosine kinase as a chemotherapeutic target: is there a clinical case? Anticancer Drugs 2006;17(2):123-31
   PubMed Web of Science ®Google Scholar
• Witte ON, Rosenberg N, Paskind M, et al. Identification of an Abelson murine leukemia virus-encoded protein present in transformed fibroblast and lymphoid cells. Proc Natl Acad Sci USA 1978;75(5):2488-92
   PubMed Web of Science ®Google Scholar
• Van Etten RA. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol 1999;9(5):179-86
   PubMed Web of Science ®Google Scholar
• Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004;5(1):33-44
   PubMed Web of Science ®Google Scholar
• Pendergast AM, Witte ON. Role of the ABL oncogene tyrosine kinase activity in human leukaemia. Baillieres Clin Haematol 1987;1(4):1001-20
   PubMedGoogle Scholar
• Sawyers CL. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell 2002;1(1):13-5
   PubMed Web of Science ®Google Scholar
• Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1084-6
   PubMed Web of Science ®Google Scholar
• Chopra R, Pu QQ, Elefanty AG. Biology of BCR-ABL. Blood Rev 1999;13(4):211-29
   PubMed Web of Science ®Google Scholar
• Danhauser-Riedl S, Warmuth M, Druker BJ, et al. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996;56(15):3589-96
   PubMed Web of Science ®Google Scholar
• Resh MD. Myristylation and palmitylation of Src family members: the fats of the matter. Cell 1994;76(3):411-3
   PubMed Web of Science ®Google Scholar
• Kaplan JM, Mardon G, Bishop JM, Varmus HE. The first seven amino acids encoded by the v-src oncogene act as a myristylation signal: lysine 7 is a critical determinant. Mol Cell Biol 1988;8(6):2435-41
   PubMed Web of Science ®Google Scholar
• Pluk H, Dorey K, Superti-Furga G. Autoinhibition of c-Abl. Cell 2002;108(2):247-59
   PubMed Web of Science ®Google Scholar
• Hantschel O, Nagar B, Guettler S, et al. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 2003;112(6):845-57
   PubMed Web of Science ®Google Scholar
• Brasher BB, Van Etten RA. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory sites. J Biol Chem 2000;275:35631-7
   PubMed Web of Science ®Google Scholar
• Knighton DR, Zheng JH, Ten Eyck LF, et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 1991;253(5018):407-14
   PubMed Web of Science ®Google Scholar
• Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002;109(3):275-82
   PubMed Web of Science ®Google Scholar
• Hubbard SR. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 1997;16(18):5572-81
   PubMed Web of Science ®Google Scholar
• Hubbard SR, Wei L, Ellis L, Hendrickson WA. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 1994;372(6508):746-54
   PubMed Web of Science ®Google Scholar
• Sicheri F, Moarefi I, Kuriyan J. Crystal Structure of the Src-family tyrosine kinase Hck. Nature 1997;385:602-9
   PubMed Web of Science ®Google Scholar
• Xu W, Harrison SC, Eck MJ. Three-dimensional structure of the tyrosine kinase c-Src. Nature 1997;385:595-602
   PubMed Web of Science ®Google Scholar
• Young MA, Gonfloni S, Superti-Furga G, et al. Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell 2001;105:115-26
   PubMed Web of Science ®Google Scholar
• Nagar B, Hantschel O, Young MA, et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003;112(6):859-71
   PubMed Web of Science ®Google Scholar
• Nagar B, Hantschel O, Seeliger M, et al. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell 2006;21(6):787-98
   PubMed Web of Science ®Google Scholar
• Moarefi I, LaFevre-Bernt M, Sicheri F, et al. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature 1997;385(6617):650-3
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56(1):100-4
   PubMed Web of Science ®Google Scholar
• Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289(5486):1938-42
   PubMed Web of Science ®Google Scholar
• Nagar B, Bornmann WG, Pellicena P, et al. Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571). Cancer Res 2002;62(15):4236-43
   PubMed Web of Science ®Google Scholar
• Fabian MA, Biggs WH, 3rd, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23(3):329-36
   PubMed Web of Science ®Google Scholar
• Seeliger MA, Nagar B, Frank F, et al. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure 2007;15(3):299-311
   PubMed Web of Science ®Google Scholar
• Sawyers CL. Research on resistance to cancer drug Gleevec. Science 2001;294(5548):1834
   PubMed Web of Science ®Google Scholar
• Burgess MR, Sawyers CL. Treating imatinib-resistant leukemia: the next generation targeted therapies. Scientific World Journal 2006;6:918-30
   Google Scholar
• Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004;64(2):672-7
   PubMed Web of Science ®Google Scholar
• Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101(2):690-8
   PubMed Web of Science ®Google Scholar
• Hofmann WK, Komor M, Hoelzer D, Ottmann OG. Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. Leuk Lymphoma 2004;45(4):655-60
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2(2):117-25
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Cowan-Jacob SW, et al. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7(5):345-56
   PubMed Web of Science ®Google Scholar
• Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-Abl. Cell 2003;112(6):831-43
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7(2):129-41
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354(24):2542-51
   PubMed Web of Science ®Google Scholar
• Kimura S, Naito H, Segawa H, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005;106(12):3948-54
   PubMed Web of Science ®Google Scholar
• Craig AR, Kantarjian HM, Cortes JE, et al. A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib. J Clin Oncol 2007;25(18S):7046
   Web of Science ®Google Scholar
• Hantschel O, Rix U, Schmidt U, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007;104(33):13283-8
   PubMed Web of Science ®Google Scholar
• Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007;110(12):4055-63
   PubMed Web of Science ®Google Scholar
• Wisniewski D, Lambek CL, Liu C, et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res 2002;62(15):4244-55
   PubMed Web of Science ®Google Scholar
• La Rosee P, Corbin AS, Stoffregen EP, et al. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002;62(24):7149-53
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company. Cyclic protein tyrosine kinase inhibitors. US6596746; 2003
   Google Scholar
• Bristol-Myers Squibb Company. Cyclic protein tyrosine kinase inhibitors. US7125875; 2006
   Google Scholar
• Bristol-Myers Squibb Company. Formulations of a Src/Abl Inhibitor. WO2006121742; 2006
   Google Scholar
• Bristol-Myers Squibb Company. Formulations of a Src/Abl Inhibitor. US0251723; 2006
   Google Scholar
• Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305(5682):399-401
   PubMed Web of Science ®Google Scholar
• Das J, Chen P, Norris D, et al. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 2006;49(23):6819-32
   PubMed Web of Science ®Google Scholar
• Melnick JS, Janes J, Kim S, et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci USA 2006;103(9):3153-8
   PubMed Web of Science ®Google Scholar
• O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65(11):4500-5
   PubMed Web of Science ®Google Scholar
• Deininger MW, Druker BJ. SRCircumventing imatinib resistance. Cancer Cell 2004;6(2):108-10
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354(24):2531-41
   PubMed Web of Science ®Google Scholar
• Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109(8):3207-13
   PubMed Web of Science ®Google Scholar
• FDA News, 2006. Available from: http://www.fda.gov/bbs/topics/NEWS/2006/NEW01400.html
   Google Scholar
• Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006;66(23):11314-22
   PubMed Web of Science ®Google Scholar
• M. D. Anderson News Release, 2007. Available from: http://www.mdanderson.org/departments/newsroom/display.cfm?id=fbc2c93a-6947-4c24-9335f38e0b8d3286&method=displayfull&pn=00c8a30f-c468-11d4-80fb00508b603a14
   Google Scholar
• Atra Zenica clinical trials, 2007. Available from: http://www.astrazenecaclinicaltrials.com/Article/526024.aspx
   Google Scholar
• O'Hare T, Pollock R, Stoffregen EP, et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 2004;104(8):2532-9
   PubMed Web of Science ®Google Scholar
• Azam M, Nardi V, Shakespeare WC, et al. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci USA 2006;103(24):9244-9
   PubMed Web of Science ®Google Scholar
• Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10(3):262-7
   PubMed Web of Science ®Google Scholar
• Vertex Pharmaceuticals, Incorporated. Abl Kinase Inhibition. WO2007014250; 2007
   Google Scholar
• Giles FJ, Cortes J, Jones D, et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007;109(2):500-2
   PubMed Web of Science ®Google Scholar
• Young MA, Shah NP, Chao LH, et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006;66(2):1007-14
   PubMed Web of Science ®Google Scholar
• Merck Corporate News, 2006. Available from: http://www.merck.com/newsroom/press_releases/corporate/2006_1221.html
   Google Scholar
• Modugno M, Casale E, Soncini C, et al. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res 2007;67(17):7987-90
   PubMed Web of Science ®Google Scholar
• Nerviano News, 2006. Available from: http://www.nervianoms.com/cont/en/news/0611/0601/nerviano-medical-sciences-new-anti.asp
   Google Scholar
• O'Hare T, Eide CA, Tyner JW, et al. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci USA 2008;105(14):5507-12
   PubMed Web of Science ®Google Scholar
• Kuma Y, Sabio G, Bain J, et al. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem 2005;280(20):19472-9
   PubMed Web of Science ®Google Scholar
• Pargellis C, Tong L, Churchill L, et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002;9(4):268-72
   PubMedGoogle Scholar
• O'Hare T, Druker BJ. BIRB-796 is not an effective ABL(T315I) inhibitor. Nat Biotechnol 2005;23(10):1209-10; author reply 1210-1201
   PubMed Web of Science ®Google Scholar
• Adrian FJ, Ding Q, Sim T, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2006;2(2):95-102
   PubMed Web of Science ®Google Scholar
• Gumireddy K, Baker SJ, Cosenza SC, et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA 2005;102(6):1992-7
   PubMed Web of Science ®Google Scholar
• New York Blood Center, Inc. Peptide inhibitors of Abl kinases. WO2007064647; 2007
   Google Scholar
• Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007;117(9):2562-9
   PubMed Web of Science ®Google Scholar
• Burgess MR, Skaggs BJ, Shah NP, et al. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 2005;102(9):3395-400
   PubMed Web of Science ®Google Scholar
• O'Hare T, Walters DK, Stoffregen EP, et al. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res 2005;11(19 Pt 1):6987-93
   PubMed Web of Science ®Google Scholar
• Weisberg E, Catley L, Wright RD, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 2007;109(5):2112-20
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company. Methods of indentifying and treating individuals exhibiting mutant Bcr/Abl kinase polypeptides. WO2007109527; 2007
   Google Scholar
• Bristol-Myers Squibb Company. Combination of a Src kinase inhibitor and a BCR-Abl inhibitor for the treatment of proliferative diseases. WO2006052810; 2006
   Google Scholar
• Novartis. Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia. US0149539; 2007
   Google Scholar
• Cortes J, Quintas-Cardama A, Garcia-Manero G, et al. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer 2007;110(9):2000-6
   PubMed Web of Science ®Google Scholar
• Cortes J, Jabbour E, Daley GQ, et al. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 2007;110(6):1295-302
   PubMed Web of Science ®Google Scholar
• Novartis. Pharmaceutical combination of Bcr-Abl and Raf inhibitors. WO2006089781; 2006
   Google Scholar
• Ramot at Tel Aviv University Ltd. Treatment of hematological malignancies with Fts and a Bcr-Abl tyrosine kinase inhibitor. WO2007116396; 2007
   Google Scholar
• Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006;108(7):2332-8
   PubMed Web of Science ®Google Scholar
• DeLano WL. The PyMOL Molecular Graphics System. In. 0.82 edition. San Carlos: Delano Scientific; 2002
   Google Scholar